The PASTEUR Act is not the way for the US government to address antimicrobial resistance

The US government’s PASTEUR Act, which aims to encourage antimicrobial research and development, is not the best approach to combat antimicrobial resistance. The Act would increase the prices of PASTEUR-supported antimicrobials, negatively impacting access to new products, compromise stewardship of resulting antimicrobials, and be inefficient in incentivizing meaningful innovation. The MSF analysis suggests that the US government should expand its role in encouraging antimicrobial R&D, using other means such as expanding investment in public and non-profit R&D, to ensure stewardship, equitable access, and public health-significant innovation.